Yu KD, Ye FG, He M, et al. - In this phase 3 randomized clinical trial with 647 patients, researchers investigated whether a paclitaxel-plus-carboplatin (PCb) as adjuvant therapy in women with operable triple-negative breast cancer (TNBC) can afford superior benefit vs a standard-dose CEF-T regimen (cyclophosphamide, epirubicin, and fluorouracil followed by docetaxel). This study was performed at 9 cancer centers and hospitals in China. Experts compared 6 cycles of PCb with a standard-dose regimen of 3 cycles of cyclophosphamide, epirubicin, and fluorouracil followed by 3 cycles of docetaxel (CEF-T). Longer disease-free survival (DFS) time was noted in patients treated with PCb vs CEF-T. Similar results were noted for distant DFS and relapse-free survival. The groups did not differ statistically significantly in terms of overall survival. Overall, experts concluded that a paclitaxel-plus-carboplatin regimen affords an effective alternative adjuvant chemotherapy option for patients having operable TNBC. Besides, subsets of TNBC sensitive to PCb should be further examined in the era of molecular classification.